Buyout Firm EQT to Acquire Qiagen for $10.8 Billion
The boards said the buyout gives Qiagen more flexibility to invest long term while delivering shareholders certain cash value and suspending full-year guidance.
- On Wednesday, Swedish private equity firm EQT agreed to acquire molecular testing company Qiagen for about $12.1 billion cash, taking the diagnostics provider private after years of merger attempts.
- Following a comprehensive strategic review, Qiagen's Supervisory Board and Managing Board concluded private ownership offers greater flexibility for long-term growth, ending nearly seven years of on-and-off merger-and-acquisition activity.
- EQT's offer represents an 8.6% premium above Qiagen's closing stock price Wednesday. Partner Matteo Thun-Hohenstein stated, "We are proud to partner with Qiagen's highly talented employees."
- Qiagen's boards recommend that shareholders tender their shares into the takeover offer, which requires a minimum acceptance threshold of 50% of outstanding share capital. The deal is expected to close in mid-2027.
- Qiagen has suspended its full-year guidance due to the planned acquisition. If regulatory approvals delay closing beyond 10 months, the company may elect to pay shareholders an interim dividend of up to $0.47 per share.
42 Articles
42 Articles
The pharmaceutical service provider Qiagen is promoted by a Swedish financial investor, who provides a billion-dollar offer for the diagnostics group.The Swedish financial investor EQT makes serious and wants to take over the laboratory service provider and diagnostics group Qiagen. EQT wants to pay 46.50 euros in cash per share via a vehicle, in which also the state fund of Abu Dhabi and the Canadian pension fund CPP Investments are to be invol…
Reformatorisch Dagblad
The German-Dutch biotechnology company Qiagen is being acquired by the Swedish investor EQT for 10.8 billion euros. The company is active in laboratory testing and pharmaceutical molecular research. It is one of the largest acquisitions in the European medical sector this year.
Zeit Online
The pharmaceutical service provider Qiagen is promoted by a Swedish financial investor, who submits an offer for the Dax Group.
Qiagen is always the subject of takeover speculation. According to a report, EQT has now made a binding offer. Competition is also involved.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
